Warszawski Uniwersytet Medyczny
Law and Forensic Science, Volume 18 (2019/2)
Submitted: January 22, 2019
Abstract: The problem of falsifications of medical products WHO applies to 1% of the value of drugs sold in highly industrialised countries and 10% of countries with low and very low income. Polish Pharmaceutical Law regulations in the field of crime of falsification of medicinal products and active substances is a result of the implementation of the Directive 2001/83/EC as amended by Directive 2011/62/EU (Falsified Medicines Directive). The article 124b has been introduced as the most significant transposition of Directive and according to this article manufacture, delivering and sharing, as well as storage to provide falsified medical products or falsified active substances is punished with fine, restriction of liberty or imprisonment of up to five years. This is an intentional crime, no-effect and widespread. Application of the Pharmaceutical Law regime is possible provided that the counterfeit product meets the requirements for the medicinal product. Polish legal solutions were positively evaluated in the report on the implementation of Article 118a of the Falsified Medicines Directive by the legislators of the Member States, prepared by the Directorate-General for Health and Food Safety for the European Parliament and the Council. Unfortunately, the implementation of the EU recommendations on educating the public about the risks of falsified medicines leaves a lot to be done in this regard. It is worth noting that different concepts are used in the field of drug forgery crimes – counterfied medicines, falsified medicines, substandard medicines or fake medicines. They all differ from each other, although they describe the same problem. Ministry of justice statistics show a very low percentage of convictions (0.014%) from the provisions of criminal articles of Pharmaceutical Law compared with all convicted adults in Poland in the years 2002-2017. With the growing phenomenon of selling drugs of unknown origin on the Internet – it’s worth asking if we have a problem with the detection of crime of falsifications or in the case of Article 124b of the Pharmaceutical Law, we are already dealing with desuetudo?
Keywords: falsified medical products, Falsified Medicines Directive, Pharmaceutical Law
Brülsi, H., Wyer, D. (2016), Pharmaceutical Cargo Theft in Europe – A
Realistic View Of The Current Trends, Challenges, And Financial Impacts
EMEA Intelligence Analysts, FreightWatch International, Retrieved in
October 7, 2018 from: https://files.carrier.com/sensitech/en/contentimages/-FWIEuropeanPharmaweb.pdf.
Ekwall, D., Brülsi, H. & Wyer, D. (2015), Theft of pharmaceuticals during transport in Europe, Journal of Transportation Security, (10)2015, Retrieved in October 7, 2018, from: DOI: 10.1007/s12198-015-0162-x.
Fijałek, Z. (2016), Fałszywe i substandardowe produkty farmaceutyczne — kradzieże cargo. Świat Przemysłu Farmaceutycznego, (3)2016, 2-5.
Davies, G. (2016), Polish Police Raid \’world\’s Largest\’ Fake Viagra Factory Worth At Least £4million, Retrieved from: http://www.dailymail.co.uk/news/article-3801640/They-expect-stiff-sentence-Polish-police-raid-world-s-largest-fake-Viagra-factory-worth-4million.html.
Isles M. (2017), What\’s in a Word? Falsified/Counterfeit/Fake Medicines – The Definitions Debate, April 4, 2017, Medicine Access @ Point of Care, Review Article, Retrieved in May 26, 2017, from: https://doi.org/10.5301/maapoc.0000008.
Konarska-Wrzosek V. (2018) Rozdział 9 Prawa Farmaceutycznego In Bojarski M. (Ed.) Szczególne dziedziny prawa karnego. Prawo karne wojskowe, skarbowe i pozakodeksowe. System prawa karnego. Tom 11, Warszawa: Wydawnictwo C.H. Beck.
Malinowski, A. (2017), Logika dla prawników. Warszawa: Wolters Kluwer.
Ożóg, M. (2010), System handlu produktem leczniczym i produktami pokrewnymi. Problematyka prawna. Warszawa: Wydawnictwo LexisNexis, pp. 53-60.
Sobol, E. (2003), Nowy Słownik Języka Polskiego, Warszawa: Wydawnictwo Naukowe PWN.
Stroetmann, K, Rennoch, J., Sinn, A., Berg, M., Möller, U., Maly, S., (2017), European Commission- Sinn- ZEIS Centre for European and International Studies – Study on the Transposition Measures Of Member States in Relation To the Pharmaceutical Legislation (art. 118a Of Directive 2001/83/EC): Final Report. Retrieved from: https://publications.europa.eu/en/publication-detail/-/publication/a1201026-fb39-11e7-b8f5-01aa75ed71a1/language-en/format-PDF/source-62239868.
Wilk, L. (2017), Komentarz do art. 124b. Prawa Farmaceutycznego. In Mozgawa M. (Ed.) Pozakodeksowe przestępstwa przeciwko zdrowiu, Warszawa: Wolters Kluwer.
Wilk, L.,(2018) Komentarz do art. 124, In: Ogiegło L. (ed.), Komentarz do ustawy Prawo farmaceutyczne, Warszawa: Wydawnictwo C.H. Beck.